Spotify Technology vs Viatris Inc — how do they compare? Spotify Technology trades at $523.66 (market cap $108.68B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Spotify Technology is far larger — about 5.7× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| SPOT | VTRS | |
|---|---|---|
Market Cap | $108.68B | $19.09B |
Sector | Media | Health |
52-Week High | $738.53 | $17.86 |
52-Week Low | $412.75 | $9.49 |
Enterprise Value | $98.31B | $31.21B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $528.64, down 2.54% on the day, but maintains a bullish technical outlook with strong fundamental momentum. The company reported record profitability with net income reaching $2.21 billion in 2025, representing a 12.87% margin, while revenue grew to $17.19 billion. Recent news highlights a $1.5 billion share repurchase authorization and ongoing subscriber growth, though Q2 2026 earnings missed expectations.
The stock presents a compelling growth story with expanding margins and positive cash flow generation, but faces valuation risks with a P/E of 28.61. Analyst consensus remains bullish with a $590.29 price target, representing 11.7% upside potential. Key risks include execution pressure to justify premium valuation and competitive threats in the audio streaming space.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →